Ilorasertib

参考资料仅供科学研究，不可用于个人用途。

货号：BCP07256CAS号：1227939-82-3纯度：98%

在线咨询

购买咨询

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	1227939-82-3	货号	BCP07256
关联产品	1847485-91-9（Ilorasertib hydrochloride ）
中文名	Ilorasertib
英文名	Ilorasertib
中文别名
英文别名	ABT348;ABT 348; Abbott 968660; ABT-348;
SMILES	O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2
化学名称
分子式	C25H21FN6O2S	分子量	488.54
纯度	98%	配送	惯例下常温包邮
产品描述	ABT-348, is a novel potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases and is currently in Phase I clinical trials. ABT-348 is is an ATP-competitive multitargeted kinase inhibitor with IC50s for inhibiting binding Aurora B (7 nM), C (1 nM), and A (120 nM), and also inhibits RET tyrosine kinase, PDGFRβ, and Flt1 with IC50s of 7 nM, 3 nM and 32 nM.ABT-348 has nanomolar potency (IC50) for inhibiting binding and cellular auto-phosphorylation of Aurora B (7 and 13 nM), C (1 and 13 nM) and A (120 and 189 nM). Based upon its unique spectrum of activity, ABT 348 was evaluated and found effective in representative solid tumor (HT1080 and MiaPaCa, tumor stasis) and hematological malignancy (RS4;11, regression) xenografts. These results provide the rationale for clinical assessment of ABT-348 as a therapeutic agent in the treatment of cancer.